newsfilter
← Latest News
PR Newswire·

Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer

SAN DIEGO, Sept. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis